RAPP at a glance
Rapport Therapeutics, Inc. (RAPP, SEC CIK 2012593) filed its latest 10-K annual report on March 10, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Rapport Therapeutics, Inc. (RAPP) shares worth $424.6 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by HEALY JAMES on October 28, 2026 of 952,380 shares at $21.00 per share.
- In the last 90 days, RAPP insiders reported 11 open-market purchases ($22.0M) and 14 open-market sales ($4.5M) on Form 4, a net purchase of $17.6M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 11 buys · 14 sells
- Net +$17.6M
- 13F holders
- 24 funds
- $424.6M · −2 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Quarterly revenue: $0, consistent with no product sales; nine-month collaboration revenue $20.0M vs $0
- Operating margin: (100.0%) vs (100.0%) YoY, net loss $40.2M vs $26.9M
- Worst performance: RAP-219 R&D costs $17.5M, up $8.7M YoY, driven by Phase 3 development
- Cash, equivalents and short-term investments $395.0M; operating cash use $96.1M for nine months
- Outlook: Phase 3 FOS trials enrolling; expenses expected to increase substantially; funding projected through 2029
Risk Factors
- Newly expanded AI/ML risk: EU AI Act and emerging U.S. state laws could impose costly governance, transparency, monitoring and human-oversight requirements
- Most materially updated regulatory risk: FDA’s June 2026 draft guidance may permit one pivotal trial, but FDA retains discretion to require additional clinical data
- Privacy compliance exposure: GDPR penalties can reach €20 million or 4% of annual global revenues
- Near-term clinical risk: RAP-219 Phase 3 programs face delays from enrollment, safety, efficacy or regulatory requirements
- Financial risk: $172.5 million of 2.25% convertible senior notes mature in 2032
AI summary of the RAPP 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results and business highlights announced for quarter ended September 30, 2026
- Full financial figures and operating updates available in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Phase 2 bipolar mania success: 3.1-point placebo-adjusted YMRS improvement, supporting RAP-219 expansion beyond epilepsy
- Safety favorable, but TEAE discontinuations 3.2% versus 0.8% for placebo
Item 2.03: Creation of a Direct Financial Obligation
- Item 2.03 links to Item 1.01, indicating a material financial obligation arose through an agreement
- Investors should review Item 1.01 for obligation amount, payment terms, interest rate, maturity and use of proceeds
Item 3.02: Unregistered Sales of Equity Securities
- PIPE shares sold privately to accredited investors under Section 4(a)(2) exemption
- Shares unregistered, creating resale restrictions and potential future registration needs
Item 2.02: Results of Operations and Financial Condition
- Preliminary cash, equivalents and short-term investments of approximately $395.0 million as of September 30, 2026
- Liquidity disclosure accompanied underwritten offerings, potentially supporting ongoing clinical development and operations
Item 1.01: Entry into a Material Definitive Agreement
- $215.7M net equity proceeds, including 11,190,476 shares or pre-funded warrants plus 1,428,571 exercised option shares
- $166.8M net convertible-note proceeds, adding $172.5M principal at 2.25% interest due December 1, 2032
Item 8.01: Other Events
- Phase 2 met its primary endpoint: YMRS improvement 3.1 points versus placebo at Week 3, p=0.045
- Secondary mania-severity endpoint also significant: 0.4-point improvement versus placebo, p=0.024
Item EX-99.1: Item EX-99.1
- Phase 2 met primary and secondary endpoints: YMRS improvement 3.1 points versus placebo, p=0.045, CGI-BP improvement 0.4 points, p=0.024
- RAP-219 reduced YMRS 15.4 points from baseline versus 12.3 points for placebo at Week 3
Item EX-99.2: Item EX-99.2
- Phase 2 bipolar mania trial met primary and secondary endpoints, supporting RAP-219 advancement into Phase 3
- YMRS improvement 3.1 points versus placebo at Week 3, p=0.045, with RAP-219 improvement of 15.4 points
Item 7.01: Regulation FD Disclosure
- Positive topline Phase 2 results announced for RAP-219 in bipolar mania
- Conference call and webcast scheduled October 20, 2026 to discuss trial data
AI summaries of RAPP 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for RAPP
Don't miss the next RAPP filing
- Alerts as it files. A push when RAPP files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut RAPP, by share count.
- Ask anything. An AI agent that reads every RAPP filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Third Rock Ventures V, L.P. | A | Oct 30, 2026 | 1,190,476 | $21.00 |
| Third Rock Ventures V, L.P. | A | Oct 30, 2026 | 238,095 | $21.00 |
| HEALY JAMES | Buy | Oct 28, 2026 | 952,380 | $21.00 |
| HEALY JAMES | Buy | Oct 28, 2026 | 6,395 | $21.00 |
| HEALY JAMES | Buy | Oct 28, 2026 | 6,933 | $21.00 |
| HEALY JAMES | Buy | Oct 28, 2026 | 3,772 | $21.00 |
| Sanchez Ramiro | Buy | Oct 23, 2026 | 3,600 | $27.35 |
| Young Wendy B. | Buy | Oct 22, 2026 | 3,789 | $26.39 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$36.2M | -$83.1M | -$125.1M |
| Net Income | - | -$78.3M | -$111.5M |
| Balance Sheet | |||
| Total Assets | $155.4M | $314.9M | $512.4M |
| Equity | -$25.6M | $305.4M | $484.7M |
| ROE | - | -25.6% | -23.0% |
| Per Share | |||
| EPS | $-23.10 | $-3.78 | $-2.86 |
| Cash Flow | |||
| Operating CF | -$27.2M | -$64.8M | -$87.5M |
| CapEx | $1.6M | $2.4M | $616K |
Source: XBRL data in Rapport Therapeutics, Inc. (RAPP)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate RAPP share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 24 | $424.6M |
| Q2 2026 | 26 | $827.9M |
| Q1 2026 | 27 | $608.8M |
| Q4 2025 | 25 | $596.9M |
| Q3 2025 | 24 | $513.5M |
| Q2 2025 | 17 | $155.7M |
| Q1 2025 | 15 | $111.3M |
| Q4 2024 | 9 | $164.9M |
- Vanguard Capital Management LLC+233.5K (+17%)
- BlackRock+181.5K (+7%)
- State Street Corp+97.8K (+12%)
- Goldman Sachs Group+63.3K (+2%)
- Two Sigma Investments+41.3K (+169%)
- Morgan Stanley−210.7K (-71%)
- T. Rowe Price Group−145.0K (-18%)
- D.E. Shaw & Co−100.5K (-47%)
- Millennium Management−86.8K (-56%)
- Prudential Financial−78.0K (-90%)
- FMR LLC (Fidelity)−7.17M
- U.S. Bancorp−14
Source: 13F-HR filings on SEC EDGAR (aggregated from 167 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
RAPP filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Oct 30, 2026 | - | - | - |
| 8-K | Oct 30, 2026 | - | Analysis | - |
| 4 | Oct 23, 2026 | - | - | - |
| 4 | Oct 23, 2026 | - | - | - |
| 4 | Oct 22, 2026 | - | - | - |
| 4 | Oct 22, 2026 | - | - | - |
| 4 | Oct 22, 2026 | - | - | - |
| 4 | Oct 22, 2026 | - | - | - |
| 4 | Oct 21, 2026 | - | - | - |
| 8-K | Oct 20, 2026 | - | Analysis | - |
| 4 | Oct 8, 2026 | - | - | - |
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Sep 24, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 29, 2026 | - | - | - |
| 4 | Jul 15, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
RAPP SEC filings: frequently asked questions
Are RAPP insiders buying or selling?
In the last 90 days, Rapport Therapeutics, Inc. (RAPP) officers, directors and 10% owners reported 11 open-market purchases worth $22.0 million by 7 insiders and 14 open-market sales worth $4.5 million by 3 insiders on Form 4, a net purchase of $17.6 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold RAPP stock?
As of September 30, 2026, the largest Rapport Therapeutics, Inc. (RAPP) holders among the 13F filers tracked by SignalX were Goldman Sachs Group ($99.9 million), BlackRock ($96.8 million), Johnson & Johnson ($60.0 million), Vanguard Capital Management LLC ($53.1 million), State Street Corp ($30.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did RAPP report in its latest 8-K?
Rapport Therapeutics, Inc. (RAPP) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results and business highlights announced for quarter ended September 30, 2026.
What are the latest RAPP SEC filings?
Rapport Therapeutics, Inc. (RAPP) filed its latest 10-K annual report on March 10, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 3, 2026.
What is RAPP's SEC CIK number?
Rapport Therapeutics, Inc. (RAPP)'s SEC Central Index Key (CIK) is 2012593. EDGAR lists every RAPP filing under that number.
Ask anything about RAPP
The research agent reads RAPP's filings, financials, insider trades and 13F holders, then answers with sources.